A Phase 2a/2b Randomized, Placebo-Controlled Clinical Study to Evaluate the Safety and Efficacy of MK-1942 as Adjunctive Therapy in Participants with Mild to Moderate Alzheimer’s Disease Dementia
This research study, called a clinical trial, is exploring a new medicine named MK-1942. It's for people who have been diagnosed with mild to moderate Alzheimer's disease. The main goals are to find out if MK-1942 is safe to use and whether it can improve memory and thinking skills. Participants will be randomly given either the new medicine or a 'dummy pill' (placebo) – neither they nor their doctors will know which one they're receiving. This helps make sure the results are fair. The study will look closely at any side effects and how people's thinking abilities change over 12 weeks. This is an early stage of testing, known as a Phase 2 trial, to see if the medicine holds promise for further research.
At a glance
What is this study about?
This study is testing a new medicine called MK-1942 for people who have Alzheimer's disease that is mild to moderate. Alzheimer's is a condition that affects memory, thinking, and daily activities. The study aims to find out two main things: first, if the new medicine is safe for people to take, and second, if it can help improve or slow down changes in memory and thinking. It's an important step in trying to find better treatments for Alzheimer's.
In this type of study, some people will get the new medicine (MK-1942), and others will get a 'dummy pill' that looks exactly the same but has no active medicine in it. This is called a *placebo*. Giving some people a placebo helps the researchers fairly compare the effects of the new medicine. Neither you nor your doctor will know if you're taking the real medicine or the placebo, which helps ensure the results are accurate.
The researchers will be carefully checking how your memory and thinking skills change over 12 weeks. They will also keep a close eye on any side effects you might experience. This information will help them decide if MK-1942 works well enough and is safe enough to be tested in larger studies in the future.
Key takeaways
- This study is testing a new medicine for mild to moderate Alzheimer's disease.
- It aims to find out if the medicine is safe and if it helps with memory and thinking.
- Some participants will receive the active medicine, others will receive a dummy pill.
- The study lasts for 12 weeks with regular check-ups.
- Participation is voluntary, and you can leave the study at any time.
- This is an early-stage study to see if the medicine holds promise.
Who may be eligible?
This study is looking for both men and women to take part. To be considered, you need to be an adult, at least 18 years old. There isn't an upper age limit, so people of all adult ages can be considered.
More importantly, you must have been diagnosed with Alzheimer's disease, and your doctor would describe it as 'mild to moderate'. This means your symptoms are noticeable but not yet very severe. The study doctors will perform some tests and checks to make sure you fit these specific criteria for the research.
Could this study suit you?
Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.
- Are you 18 years old or older?
- Have you been diagnosed with Alzheimer's disease?
- Has your doctor described your Alzheimer's as 'mild to moderate'?
- Are you able to attend regular clinic visits for about 12 weeks?
What does participation involve?
If you decide to take part, you would be involved for about 12 weeks. You would have regular visits to the clinic where study doctors and nurses would check on your health and memory. During these visits, you'd be asked to take a capsule, which would be either the new medicine (MK-1942) or a dummy pill (placebo). You'd also complete some tests designed to measure your memory, thinking skills, and how you manage everyday tasks. Throughout the study, the team would monitor you closely for any side effects. After the 12 weeks, there will be a final check-up to make sure everything is okay.
Potential risks and benefits
Locations (2)
- —UnverifiedItaly
- —UnverifiedSpain
Common questions
What is Alzheimer's disease?
Alzheimer's disease is a brain condition that gradually causes problems with memory, thinking, and behaviour. It's the most common cause of dementia.
What does 'mild to moderate' Alzheimer's mean?
This means your Alzheimer's symptoms are noticeable and might affect your daily life a bit, but you can still do many things independently. It's not yet in the very advanced stages.
What is a 'Phase 2' study?
Phase 2 means this is an early stage of testing where researchers are mainly looking at how safe the new medicine is and if it shows any signs of working. It's not as large as later studies.
What is a 'placebo'?
A placebo is a 'dummy pill' that looks exactly like the real medicine but has no active ingredients. It helps researchers compare the new medicine's effects fairly.
Will I know if I'm getting the real medicine or the placebo?
No, neither you nor your study doctor will know whether you're receiving the active medicine or the placebo. This helps ensure unbiased results.
How to find out more
Always speak to your GP or specialist before deciding to take part in a study.
Discussion
Community discussion
Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.